MedTrace Logo

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

NCT06046742 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-03-13

No results posted yet for this study

Summary

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Conditions

Interventions

BIOLOGICAL

M1-c6v1

Intravenous drip administration

Sponsors & Collaborators

  • Guangzhou Virotech Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou Virotech Pharmaceutical Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2026-06-30
Completion
2026-12-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06046742 on ClinicalTrials.gov